Shilpa Medicare's US-based subsidiary files lawsuit against Novartis Pharma for patent infringement

Shilpa Pharma is seeking relief for the infringement of the US Patent entitled "Fingolimod Polymorph and Their Processes".

Apr 27, 2021 02:04 IST India Infoline News Service

Shilpa Medicare
Shilpa Medicare has announced that its US operating company, Shilpa Pharma filed a patent infringement lawsuit against Novartis Pharmaceutical Corporation in the United States District Court for the District of Delaware seeking relief for the infringement of the US Patent entitled "Fingolimod Polymorph and Their Processes".

Shilpa Medicare said, "Shilpa invest heavily in R&D as we want to provide the patients with the best affordable pharmaceutical solutions, which resulted in more than 466 patent applications worldwide including 70 patent applications of which 30 patents have been granted in the United States alone."

Shilpa is a global brand in manufacturing and supplying affordable Active Pharmaceutical Ingredients (APIs), generic and innovative Formulations globally in different markets. As a global brand in Active Pharmaceutical Ingredients, generic and Innovative Formulations, Shilpa re-invests a significant portion of its revenue in R&D each year.

At around 2.30 pm, Shilpa Medicare was trading at Rs422 per piece down by 1.55% on Sensex. 

Related Story

Open Free Demat Account (Rs699)